AI Science Tracker
EN

Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China

1 discovery from 2022

Discoveries

Miniaturized microfluidic-based nucleic acid analyzer to identify new biomarkers of biopsy lung cancer samples for subtyping

Source check: Source checked. Not independent scientific confirmation.

Finding: A microfluidic RT-LAMP analyzer measured 11 lung-cancer biomarkers in small biopsy samples; a machine-learning model classified subtypes across 86 clinical samples with average AUC 0.934. The result is a bounded single-study diagnostic evaluation, not evidence of improved patient outcomes.

Technology: A machine-learning classifier groups lung-cancer subtypes using 11 nucleic-acid biomarkers measured by microfluidic RT-LAMP.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
A machine-learning classifier groups lung-cancer subtypes using 11 nucleic-acid biomarkers measured by microfluidic RT-LAMP.
Test and result
A microfluidic RT-LAMP analyzer measured 11 lung-cancer biomarkers in small biopsy samples; a machine-learning model classified subtypes across 86 clinical samples with average AUC 0.934
Limitation / still unknown
The result is a bounded single-study diagnostic evaluation, not evidence of improved patient outcomes.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9466282/ · https://pubmed.ncbi.nlm.nih.gov/36105308/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.